Nicholas Investment Partners, LP Crispr Therapeutics Ag Transaction History

Nicholas Investment Partners, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 13, 2020	SELL	$33.68 - $62.53 $1.57 Million - $2.91 Million	-46,541 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$36.68 - $73.13 $929,617 - $1.85 Million	25,344 Added 119.56%	46,541 $2.84 Million
Q3 2019 Nov 13, 2019	BUY	$40.99 - $52.56 $595,707 - $763,854	14,533 Added 218.08%	21,197 $869,000
Q2 2019 Aug 09, 2019	BUY	$35.45 - $48.2 $236,238 - $321,204	6,664 New	6,664 $314,000
Q4 2018 Feb 14, 2019	SELL	$22.73 - $42.34 $1.96 Million - $3.66 Million	-86,353 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$44.35 - $65.71 $12,418 - $18,398	-280 Reduced 0.32%	86,353 $3.83 Million
Q2 2018 Aug 14, 2018	BUY	$42.62 - $73.59 $261,814 - $452,063	6,143 Added 7.63%	86,633 $5.09 Million
Q1 2018 May 15, 2018	BUY	$23.52 - $58.17 $1.89 Million - $4.68 Million	80,490 New	80,490 $3.68 Million

493

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.97B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Nicholas Investment Partners, LP, based on Form 13F filings with the SEC.

Stay updated on Nicholas Investment Partners, LP with notifications on news.